Cullinan Oncology Inc
Research Cullinan Oncology Inc (CGEM) on Bullrun: market cap USD 1.48B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerCGEM
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 1.48B
- Financial periodQ2 2026
- RevenueUSD 0
- Net income-USD 53.70M
- Free cash flow-USD 38.22M
Valuation Snapshot
latest market cap is USD 1.48B.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 0 | -USD 219.88M | -USD 175.80M | n/a | -3.35 | USD 88.33M | USD 2.68M | USD 408.73M |
| FY2024 | USD 0 | -USD 167.58M | -USD 145.30M | n/a | -2.79 | USD 83.01M | USD 2.15M | USD 590.33M |
| FY2023 | n/a | -USD 155.10M | -USD 134.48M | n/a | -3.69 | USD 98.43M | USD 3.59M | USD 453.70M |
| FY2022 | USD 0 | USD 111.21M | -USD 127.80M | n/a | 2.38 | USD 156.15M | USD 1.13M | USD 535.03M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 1.48B | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 623.53M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 712.66M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 435.93M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 482.90M | 4.8 | n/a | n/a |
| 2021 | 2021-12-31 | USD 683.43M | n/a | n/a | n/a |
About Cullinan Oncology Inc
Cullinan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for autoimmune diseases and cancer in the United States. It engages in the development of CLN-978, a CD19xCD3 bispecific T cell engager for autoimmune diseases in Phase 1 clinical trials; Velinotamig, a BCMAxCD3 bispecific T cell in Phase 1 clinical trials in patients with autoimmune diseases;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Cullinan Oncology Inc's market cap?
Cullinan Oncology Inc's market capitalization is USD 1.48B.
What does Cullinan Oncology Inc do?
Cullinan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for autoimmune diseases and cancer in the United States. It engages in the development of CLN-978, a CD19xCD3 bispecific T cell engager for autoimmune diseases in Phase 1 clinical trials; Velinotamig, a BCMAxCD3 bispecific T cell in Phase 1 clinical trials in patients with autoimmune diseases; and CLN-049, a FLT3xCD3 bispecific T cell engager, which is in Phase 1 clinical trials in patients with relapsed and refractory acute myeloid leukemia or myelodysplastic syndrome.